Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
Open Access
- 2 December 2020
- journal article
- research article
- Published by Elsevier BV in Acta Pharmaceutica Sinica. B
- Vol. 11 (6), 1617-1628
- https://doi.org/10.1016/j.apsb.2020.11.022
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82030105, 21738002, 21807113)
- National Key R&D Program of China (2020YFA0509100)
- Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-07-E00073)
This publication has 46 references indexed in Scilit:
- Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB PathwayJournal of Medicinal Chemistry, 2014
- Small‐Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome SystemAngewandte Chemie, 2014
- Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesisExperimental Hematology, 2013
- Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein InteractionJournal of Medicinal Chemistry, 2012
- Targeting IAP proteins for therapeutic intervention in cancerNature Reviews Drug Discovery, 2012
- The Regulation of the p53-mediated Stress Response by MDM2 and MDM4Cold Spring Harbor Perspectives in Biology, 2009
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000